Oral Biolife taps Thomas J. Corrigan as finance chief

Oral Biolife named healthcare finance veteran Thomas J. Corrigan as vice president of finance as the Bethlehem, Pennsylvania biotech advances its regenerative platform. The hire is meant to strengthen financial operations, investor readiness and fundraising support as the company pushes toward commercialization.

Why it matters: - Oral Biolife is building the financial infrastructure needed to support future growth, fundraising and commercialization. - The company is advancing a non-surgical, piezoelectric regenerative platform aimed at dental and orthopedic indications. - Corrigan’s background in healthcare finance adds senior-level experience at a stage when operational discipline and capital planning matter.

What happened: - Oral Biolife appointed Thomas J. Corrigan, CPA, as vice president of finance. - The company announced the hire on July 9, 2026, from Bethlehem, Pennsylvania. - Corrigan will lead financial strategy, capital management, investor readiness, financial controls and operational planning.

The details: - Corrigan brings more than 25 years of experience in financial strategy, capital allocation, mergers and acquisitions and business transformation across global healthcare organizations. - He spent 17 years in finance leadership roles at Novartis. - Corrigan previously held finance leadership positions at Johnson & Johnson and PwC. - His work has included evaluating investments, managing complex portfolios, supporting growth initiatives and aligning financial strategy with long-term value creation. - Corrigan is a Certified Public Accountant. - He also served as a founding board member of Avery's Hope, a nonprofit that supports families affected by rare diseases. - Oral Biolife’s Founder and President Dr. Stella Vnook said Corrigan’s experience will help strengthen financial operations, support future fundraising efforts and position the company for long-term growth. - Corrigan said he sees Oral Biolife as having a differentiated platform addressing large, underserved markets in dental and orthopedic care. - Corrigan said he will focus on building the financial infrastructure to support commercialization, strategic growth and long-term value creation.

Between the lines: - The hire suggests Oral Biolife is moving from platform development toward the operational structure needed for scaling. - Adding a finance leader with large-company healthcare experience can signal readiness for fundraising, partnerships or other capital-intensive milestones. - Corrigan’s mix of corporate finance and nonprofit board experience points to both technical financial oversight and stakeholder management.

What's next: - Oral Biolife will look to use Corrigan’s leadership to support commercialization planning and future capital efforts. - The company is expected to keep building out the financial and operational systems behind its regenerative technology platform. - Corrigan will play a central role in long-term growth initiatives as the business advances across dental and orthopedic markets.